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ALSPAC birth cohorta b s t r a c t
Objective: Interleukin 6 (IL-6) levels are commonly elevated in patients with depression and psychosis
and in people who are at risk of developing these disorders. A common, functional variant in the IL6R
gene (IL6R Asp358Ala; rs2228145 A > C) is known to dampen down inflammation by impairing IL6R sig-
naling. We have examined the association of Asp358Ala with diagnosis of depression and psychosis,
serum IL-6, CRP levels, and a number of risk factors commonly linked with inflammation, depression
or psychosis. We predicted that if IL-6 were related to depression/psychosis risk causally, rather than
due to confounding, Asp358Ala would be associated with risk of these disorders, serum IL-6, CRP levels,
but not with any of the confounders.
Method: We used data from the population-based ALSPAC birth cohort. Serum IL-6 and CRP levels were
measured at age 9 years. Psychotic disorder, ICD-10 diagnosis of severe depressive episode, and total
depression score were assessed at age 18 years. IL6R Asp358Ala was genotyped using the Illumina
HumanHap550 quad genome-wide SNP genotyping platform. Risk factors assessed include sex, body
mass index, social class, ethnicity, maternal education, birth weight, gestational age, maternal post-
natal depression, childhood psychological and behavioral problems, and total IQ score.
Results: Asp358Ala was associated with decreased risk of severe depression and/or psychosis; adjusted
odds ratio for those with CC, compared with AA, genotype was 0.38 (95% CI, 0.15–0.94). The variant
was associated with increased serum IL-6 levels (P = 5.5  1022) but decreased serum CRP levels
(P = 3.5  105), consistent with an anti-inflammatory effect downstream of IL-6. Asp358Ala was not
associated with total depression score. Asp358Ala was not associated with any of the other risk factors
commonly linked with inflammation, depression or psychosis (all P > 0.20).
Conclusions: The findings provide further evidence that the IL-6/IL6R pathways are involved in pathogen-
esis of severe depression and psychosis, and may be novel therapeutic targets. Previously reported asso-
ciations between IL-6, depression and psychosis are unlikely to be fully explained by confounding. Based
on a small number of cases, findings from the current study need replication in other samples.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Experimental, clinical and epidemiological studies indicate that
inflammatory cytokines may contribute to pathogenesis of depres-
sion and psychosis, of which interleukin 6 (IL-6) is one of the lead-
ing candidates. Injecting mice with IL-6, which controls serotonin
transporter levels and consequently serotonin reuptake (Kong
et al., 2015), leads to depression-like behaviour (Sukoff Rizzo
et al., 2012). Inhibiting circulating IL-6 with a monoclonal antibody
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stress (Hodes et al., 2014). In healthy volunteers, inflammation-
induced mood deterioration and associated changes in the subgen-
ual cingulate activity and mesolimbic connectivity are mediated by
circulating IL-6 levels (Harrison et al., 2009). In patients with
depression (Dowlati et al., 2010; Goldsmith et al., 2016;
Haapakoski et al., 2015; Howren et al., 2009) and psychosis
(Miller et al., 2011; Miller et al., 2013; Potvin et al., 2008;
Upthegrove et al., 2014) who are acutely unwell, concentrations
of IL-6 and other inflammatory markers are elevated compared
with controls, which tend to normalize after recovery but continue
to be elevated in treatment resistant patients (Goldsmith et al.,
2016; Maes et al., 1997; O’Brien et al., 2007). Treatment with a
monoclonal antibody against IL-6 receptor (IL6R) may improve
symptoms of depression (Kappelmann et al., 2016) and
schizophrenia (Miller et al., 2016).
Epidemiological studies based on prospective cohorts suggest,
higher IL-6 levels are associated with cognitive symptoms of
depression (Gimeno et al., 2009) and depression severity subse-
quently (Khandaker et al., 2014). Our work based on a
population-based prospective birth cohort indicates that higher
levels of IL-6 in childhood at age 9 years are associated with
increased risks of developing depressive and psychotic symptoms
subsequently in early-adulthood at age 18 years in a linear, dose-
response fashion (Khandaker et al., 2014). Elevated IL-6 levels in
childhood are also associated with persistent depressive symptoms
subsequently during the second decade of life (Khandaker et al.,
2017). Confounding is an important alternative explanation for
epidemiological observations. Although evidence for associations
between IL-6, depression and psychosis remained after controlling
for a number of potential confounders, residual confounding from
unmeasured factors still might account for these associations.
We have carried out a targeted genetic association analysis to
examine whether association between serum IL-6 levels, depres-
sion and psychosis are consistent with a causal role of inflamma-
tion in these disorders or whether these associations could be
explained by confounding (see below). To this end, we have
focused on a common, functional single nucleotide polymorphism
(SNP) in the IL6R gene (IL6R Asp358Ala; rs2228145 A > C; formerly
known as rs8192284), which is known to regulate IL-6 bioactivity.
Cell-based experiments have previously shown that the minor
358Ala allele decreases inflammatory activity by reducing surface
expression of IL6R on CD4 + T lymphocytes and monocytes, which
results in decreased responsiveness of cells to IL-6 (Ferreira et al.,
2013; Reich et al., 2007). The variant is associated with higher
levels of IL-6 but lower levels of CRP, and is protective for a number
of physical illnesses associated with inflammation such as coro-
nary heart disease (CHD) (Collaboration et al., 2012; Swerdlow
et al., 2012) and type-1 diabetes (Ferreira et al., 2013). The variant
is also associated with decreased risk of schizophrenia (Kapelski
et al., 2015). However, to our knowledge no study has examined
the association between Asp358Ala and depression. Furthermore,
associations between Asp358Ala and circulating IL-6 and CRP
levels have been observed in adults (Collaboration et al., 2012),
but we are not aware of any studies examining these associations
in childhood.
Based on findings from previous studies, we hypothesized that
Asp358Ala would be associated with elevated serum IL-6 but
decreased serum CRP levels at age 9 years, and with decreased
risks of depression and psychosis at age 18 years in the ALSPAC
birth cohort. We also examined the relationship between
Asp358Ala and a number of risk factors commonly linked with
inflammation, depression or psychosis (e.g., age, sex, social class,
ethnicity, body mass index, IQ). If the variant were associated with
IL-6, CRP, depression, and psychosis, but not with the confounders,
this would indicate that the variant affects psychiatric risk by alter-ing levels of inflammation. This would also indicate that previously
reported associations between IL-6, depression and psychosis are
unlikely to be fully explained by confounding (see discussion). In
addition to using depression as continuous measure, we examined
risk of severe depression defined according to ICD-10 criteria
(WHO, 1992). This is because focusing on severe illness can
increase the likelihood of detecting genetic associations for depres-
sion by reducing phenotypic heterogeneity (Converge Consortium,
2015). We also calculated risk of severe depression and/or psy-
chosis; we considered severe depression and psychosis together
due to their phenotypic and aetiological overlap (see discussion),
and to increase statistical power.2. Materials and methods
2.1. Description of cohort and sample
The ALSPAC birth cohort comprises 14,062 live births from
pregnant women resident in county Avon, a geographically defined
region in southwest of England, with expected dates of delivery
between April 1991 and December 1992 (http://www.bristol.ac.
uk/alspac/). Parents completed regular postal questionnaires about
all aspects of their child’s health and development from birth. Since
age 7, the children attended an annual assessment clinic during
which they participated in various face-to-face interviews and
physical tests. Samples sizes for the associations examined vary
because assessments for IL6R genotype, serum IL-6 concentration
at 9 years, serum CRP concentration at 9 years, depression at 18
years, and psychosis at 18 years were completed on different num-
bers of participants. We used the maximum available data to test
each association (see Tables).
2.2. Assessments of depression at age 18 years
The computerised version of the Clinical Interview Schedule
Revised (CIS-R) was self-administered by cohort participants in
assessment clinics at average age 17.8 years (SD = 0.38). The CIS-
R is a widely used, standardized tool for measuring common men-
tal disorders in large community samples (Lewis et al., 1992). In
the UK, CIS-R has been used in National Psychiatric Morbidity Sur-
vey, a household survey on 10,000 individuals representative of the
UK population, in 1993 and 2007 (Jenkins et al., 1997; Spiers et al.,
2011). The CIS-R is a fully structured assessment, suitable for
trained social survey interviewers and does not require any expert
knowledge on the part of the interviewers. As such, it can also be
administered using personal computers in which the subjects
self-complete the questionnaire (Lewis, 1994).
The CIS-R elicits responses to 14 symptoms of depression expe-
rienced in past week, and provides a diagnosis of depression
according to ICD-10 criteria. We used severe depressive episode
defined according to ICD-10 criteria as the main outcome. In addi-
tion, we used CIS-R total depression score as a continuous outcome
measure. Total depression score ranged from zero to 21, which was
calculated by summing symptom scores for depression, depressive
thoughts, fatigue, concentration, and sleep problems.
2.3. Assessments of psychotic disorder at age 18 years
Psychotic symptoms were identified through the face-to-face,
semi-structured Psychosis-Like Symptom Interview (PLIKSi) con-
ducted by trained psychology graduates in assessment clinics,
and were coded according to the definitions and rating rules for
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
(WHO, 1994). The PLIKSi has good inter-rater and test-retest relia-
bility (both kappa = 0.8) (Zammit et al., 2013). Psychotic symptoms
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occurring since age 12 were elicited: hallucinations (visual, audi-
tory); delusions (spied on, persecution, thoughts read, reference,
control, grandiosity, other); thought interference (insertion, with-
drawal, broadcasting). After cross-questioning, interviewers rated
symptoms as not present, suspected, or definitely psychotic. For
suspected or definite symptoms, interviewers also recorded fre-
quency; impact on affect, social function, educational/ occupa-
tional function; help seeking; and attributions, such as fever,
hypnopompic/ hypnogogic state, or drugs. Based on these data,
an operational definition of psychotic disorder was created as the
presence of definite psychotic symptoms not attributable to the
effects of sleep/fever, and where the symptom: (1) occurred at
least once per month over the past six months, and, (2) caused sev-
ere distress, or had a very negative impact on social/occupational
function, or led to help-seeking from a professional source
(Zammit et al., 2013).
2.4. Measurement of serum IL-6 and CRP concentrations at age 9 years
Blood samples were collected at non-fasting state at average
age 9.9 years (SD = 0.32), immediately spun and frozen at 80 C.
Inflammatory markers were assayed in 2008 after a median of
7.5 years in storage with no previous freeze-thaw cycles during
this period. IL-6 was measured by enzyme-linked immunosorbent
assay (ELISA) (R&D systems, UK), and high sensitivity CRP by auto-
mated particle-enhanced immunoturbidimetric assay (Roche UK).
All inter-assay coefficients of variation were <5%. The minimum
detection limit for IL-6 was 0.007 pg/mL, and that for CRP was
0.01 mg/L. This represents the lowest measureable analytic level
that can be distinguished from zero. In the total sample with valid
inflammatory marker data at age 9 years, IL-6 values ranged from
0.007 to 20.051 pg/mL (N = 5076), and CRP values ranged from
0.01 to 67.44 mg/L (N = 5086).
2.5. IL6R SNP selection and genotyping
The study focused on a specific functional genetic variant
(Asp358Ala; rs2228145) because it is well characterised with
regards to its effect on IL6R signaling. Asp358Ala impairs classic
IL6R signaling, and hence, dampen inflammation by reducing
membrane bound IL6R levels (Ferreira et al., 2013). Previous stud-
ies have reported associations between Asp358Ala (or variants clo-
sely linked with it) and circulating inflammatory markers
(Collaboration et al., 2012; Reich et al., 2007), CHD (Collaboration
et al., 2012; Swerdlow et al., 2012), and auto-immune diseases
such as type-1 diabetes (Ferreira et al., 2013). In total, 9912 unse-
lected participants from the ALSPAC birth cohort were genotyped
using the Illumina HumanHap550 quad genome-wide SNP geno-
typing platform by 23 and Me subcontracting the Wellcome Trust
Sanger Institute, Cambridge, UK and the Laboratory Corporation of
America, Burlington, NC, USA. After extensive quality control, high
quality genotype data were available from 8355 participants (84%
of those genotyped); rs2228145 was directly genotyped on the
array. The variant was in Hardy-Weinberg equilibrium (observed
frequencies for the common homozygotes (AA), heterozygotes
(AC), and rare homozygotes (CC) genotypes were 2892, 4000 and
1463, respectively; Chi-squared = 1.55; df = 1; P = 0.213). We re-
examined the association of rs2228145 with severe depression
and psychosis by excluding participants who were related
(identity-by-descent/ IBD cut off = 0.05).
2.6. Assessment of potential confounders
For each variable, age of assessment and available sample size
used to examine association with Asp358Ala have been presentedin the results section. Briefly, birth weight, gestational age and sex
were recorded at birth. Body mass index (weight in kg divided by
height in meter squared) was assessed around blood collection for
IL-6 assay. Age at psychiatric assessment for depression and psy-
chosis at 18 years was recorded in months. As per the UK Office
of National Statistics classification system, father’s social class
was recorded in six categories: I, II, III non-manual, III manual,
IV, V (in descending order with professionals and higher manage-
rial workers representing social class I). Mother’s highest educa-
tional achievement was recorded in four groups (secondary
school, vocational qualification, O level, A level, degree). Ethnicity
was coded as a categorical variable with the British White group
comprising 97.4% of the sample. Mother’s postnatal depression
was measured by the self-report Edinburgh Postnatal Depression
Scale administered at 8 weeks postpartum (Cox et al., 1987). IQ
was measured by the Wechsler Intelligence Scale for Children
(WISC III, 3rd UK edition) at age 8 years (Wechsler et al., 1992).
Mothers completed the parent version of the Strengths and Diffi-
culties Questionnaire (SDQ) when the study child was 7 years
old. The SDQ is an age appropriate, valid and reliable tool for mea-
suring psychological and behavioural problems in young children
(Goodman, 1997).2.7. Statistical analysis
We used logistic regression to examine the relationship
between IL6R genotype and the outcomes of severe depression,
psychosis, and severe depression and/or psychosis, coded as binary
variable. Odds ratios (ORs) for each outcome were calculated for
participants with AC and CC genotype, compared with AA geno-
type. The regression models were adjusted for sex, body mass
index, ethnicity, father’s social class, and mother’s highest educa-
tional qualification. We used linear regression to examine the rela-
tionship between CIS-R total depression score (continuous
variable) and IL6R genotype. In addition, we used one-way analysis
of variance to compare mean total depression score among three
groups defined according to IL6R genotype. We used independent
sample Kruskal Wallis test to compare distributions of total
depression scores among these groups.
The association between IL6R genotype and serum IL-6, CRP
concentrations (natural log-transformed values) was examined
using linear regression. For the associations between IL6R genotype
and psychiatric risk factors: one-way analysis of variance and lin-
ear regression were was used for continuous variable (age, birth
weight, gestational age, body mass index, mother’s Edinburgh
postnatal depression score at 8 weeks postpartum, Strengths and
Difficulties Questionnaire total difficulties score at 7 years, child’s
total Wechsler IQ score at 8 years). Chi-squared test was used for
categorical variable (sex, ethnicity, father’s social class, mother’s
education).3. Results
3.1. Association between IL6R genotype Asp358Ala (rs2228145 A>C),
severe depression and psychosis
The minor allele frequency of Asp358Ala was 41% based on
8355 participants from the ALSPAC birth cohort. Analysis for the
association between Asp358Ala and severe depression and/or psy-
chosis at age 18 years were based on 3251 participants. The sample
included 79 cases of severe depression and/or psychosis (see below
for further information). Risk of severe depression and/or psychosis
decreased in a linear fashion for each copy of the minor allele
358Ala; rs2228145 [C] (Fig. 1). The OR for severe depression and/










































Psychotic disorder at 18y
Fig. 1. Cases of Severe Depression and Psychosis at Age 18 Years Grouped by IL6R Genotype Asp358Ala (rs2228145 A > C).
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P-value = 0.010, which remained statistically significant after
adjusting for sex, body mass index, ethnicity, father’s social class,
and mother’s highest educational level (Table 1). The OR for linear
trend for association between IL6R genotype and severe depression
and/or psychosis also remained statistically significant after
adjusting for potential confounders; adjusted OR = 0.65 (95% CI,
0.44–0.95); P-value = 0.026. Analyses for the association of
Asp358Ala with severe depression and psychosis as separate out-
comes were based on 3406 and 3521 participants respectively.
These analyses revealed similar results indicating a protective
effect of the CC genotype although confidence intervals for the
ORs became wider and included the null.
Out of 3251 participants with data on IL6R genotype and diag-
nosis of severe depression and/or psychosis, 173 were related
(IBD cut off = 0.05). Sensitivity analysis after removing these par-
ticipants showed results similar to the main analysis. The OR for
severe depression and/or psychosis in those with the CC genotype
compared with those with the AA genotype was 0.34 (95% CI, 0.14–
0.82); P-value = 0.016. Evidence for this association attenuated
after adjusting for sex, body mass index, ethnicity, father’s socialTable 1
The Odds Ratios for Severe Depression and/or Psychosis at Age 18 Years in the ALSPAC Bi
Genotype Sample Case, No. (%)
Severe Depression and/or Psychosis
A/A 1127 36 (3.2)
A/C 1548 37 (2.4)
C/C 576 6 (1.0)
Linear trend 3251 79 (2.4)
Severe Depression
A/A 1176 19 (1.6)
A/C 1621 14 (0.9)
C/C 601 5 (0.8)
Linear trend 3406 38 (1.1)
Psychosis
A/A 1220 20 (1.6)
A/C 1669 29 (1.7)
C/C 632 5 (0.8)
Linear trend 3521 54 (1.5)
1 ORs have been adjusted for sex, body mass index, ethnicity, father’s social class, andclass, and mother’s highest educational level quite possibly due
to missing data for some these confounders; adjusted OR = 0.42
(95% CI, 0.17–1.04); P-value = 0.062 (Online Supplementary
Table 1). However, the adjusted OR for linear trend for association
between IL6R genotype and severe depression and/or psychosis
remained statistically significant after adjusting for potential con-
founders; adjusted OR = 0.66 (95% CI, 0.45–0.99); P-value = 0.046.
Additional sensitivity analyses using severe depression and psy-
chosis as separate outcomes also showed similar results as the
main analysis (Online Supplementary Tables 2 and 3).
In our dataset, out of 79 cases of severe depression and/or psy-
chosis, 43 participants met criteria for psychosis only (i.e., no co-
morbid severe depression) and 30 met criteria for severe depres-
sion only (i.e. no co-morbid psychosis), and 6 met criteria for both
severe depression and psychosis. We explored the relationship of
IL6R genotype with diagnosis of severe depression only and psy-
chotic disorder only. Cross-tabulation of rs2228145 genotype by
diagnosis showed that the CC genotype was protective for both
diagnoses (Online Supplementary Tables 4 and 5). This is in line
with our main analysis presented in Table 1 that examined severe
depression and psychosis as separate outcomes but ignoredrth Cohort for the IL6R Genotype Asp358Ala (rs2228145 A > C).
Odds Ratio (95% CI)
Unadjusted Adjusted1
1 [reference] 1 [reference]
0.74 (0.47–1.18) 0.70 (0.41–1.20)
0.32 (0.13–0.76) 0.38 (0.15–0.94)
0.63 (0.45–0.88) 0.65 (0.44–0.95)
1 [reference] 1 [reference]
0.53 (0.26–1.06) 0.57 (0.26–1.24)
0.50 (0.18–1.35) 0.59 (0.21–1.66)
0.64 (0.40–1.05) 0.71 (0.43–1.19)
1 [reference] 1 [reference]
1.06 (0.59–1.88) 1.09 (0.55–2.17)
0.47 (0.18–1.28) 0.38 (0.11–1.35)
0.79 (0.53–1.17) 0.75 (0.47–1.20)
mother’s highest education.
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chosis (N = 6), the percentage of participants with AA, AC and CC
genotype was the same (Online Supplementary Table 6).
3.2. Association between Asp358Ala and CIS-R depression total score
Data on CIS-R depression total score at age 18 years and IL6R
genotype were available for 3400 participants. Mean depression
score tended to decrease for each copy of the minor 358Ala [C]
allele (Table 2); however, difference in mean depression scores
among groups with AA, AC and CC genotype was not statistically
significant. Similarly, distributions of depression scores among
these groups were not significantly different. Linear regression
did not find evidence for an association between Asp358Ala and
total depression score at age 18 years (coefficient 0.114;
SE = 0.097; P = .243).3.3. Association between Asp358Ala, serum IL-6 and CRP levels and
other risk factors
Asp358Ala was strongly associated with serum IL-6 (b = 0.182;
SE = 0.019; P = 5.5  1022) and CRP concentrations at age 9 years
(b = –0.110; SE = 0.027; P = 3.5  105). For each copy of the minor
358Ala allele serum IL-6 concentration increased by about 15%
(Fig. 2; Table 3). Carriers of the homozygous minor CC genotype
had lower CRP compared with carriers of the homozygous AA
genotype, although this was not statistically significant. Asp358Ala
was not associated with any of the other risk factors commonly
linked with inflammation, depression or psychosis; all P > 0.20
(Table 4). We carried out additional analysis using linear regression
to test the association of Asp358Ala with risk factors that were
recorded as continuous variables; no evidence for association
was found; all P > 0.10 (Online Supplementary Table 7).4. Discussion
Using data from a population-based birth cohort, we report that
a common, functional variant in the IL6R gene (IL6R Asp358Ala;
rs2228145 A > C) that is known to dampen down inflammation is
associated with decreased risk of severe depression and/or psy-
chosis. The variant is associated with increased serum IL-6 levels
but decreased serum CRP levels, which is consistent with an
anti-inflammatory effect of the minor 358Ala allele downstream
of IL-6 previously reported by others (Ferreira et al., 2013).
Asp358Ala was not associated with any of the risk factors com-
monly linked with inflammation, depression or psychosis, such
as age, sex, body mass, social class, ethnicity, maternal post-natal
depression, and IQ. Taken together, these findings indicate that
the variant affects risk of major psychiatric disorder (severe
depression and/or psychosis) by altering levels of inflammation.
Previously reported associations between IL-6, depression and psy-
chosis are unlikely to be fully explained by confounders commonly
linked with inflammation, depression or psychosis. The variant
was not associated with total depression score, which indicatesTable 2
CIS-R Depression Total Score at Age 18 Years for the IL6R Genotype Asp358Ala (rs222814
IL6R Genotype Sample Depression Score, Mean (SD) Test Statistic; P-
A/A 1174 3.33 (4.15) F = 0.748; df = 2
A/C 1619 3.26 (3.95)
C/C 607 3.09 (3.82)
1 One-way analysis of variance was used to compare mean depression score among t
2 Independent Sample Kruskal Wallis test was used to compare distributions of deprethat the IL6R pathway may be relevant for severe rather than mild
depression. Based on a small number of cases the findings need
replication in other samples, but provide further evidence that
the IL-6/IL6R pathways are involved in pathogenesis of severe
depression and psychosis.
We have focused on a specific genetic variant (Asp358Ala;
rs2228145) because it is well characterised with regards to its
effect on IL6R signaling (Ferreira et al., 2013; Reich et al., 2007).
The findings are consistent with biological actions of this genetic
variant and with previous epidemiological studies reporting a pro-
tective effect of this variant for a number of physical illnesses
including CHD (Collaboration et al., 2012), atrial fibrillation
(Schnabel et al., 2011), abdominal aortic aneurysm (Harrison
et al., 2013), and type-1 diabetes (Ferreira et al., 2013). Asp358Ala
is known to dampen down inflammation by reducing membrane
bound IL-6 signaling. Although 358Ala increases transcription of
the soluble IL6R isoform and not the membrane-bound isoform,
358Ala reduces surface expression of IL-6R on CD4 + T lympho-
cytes and monocytes (up to 28% reduction per allele). Importantly,
reduced expression of membrane-bound IL-6R results in impaired
IL-6 responsiveness, as measured by decreased phosphorylation of
the transcription factors STAT3 and STAT1 following stimulation
with IL-6 (Ferreira et al., 2013). A large collaborative meta-
analysis of 82 studies has previously reported that Asp358Ala is
associated with increased levels of circulating IL-6 and sIL6R, but
decreased levels of CRP in adults (Collaboration et al., 2012). We
report that the variant is associated with increased IL-6 but
decreased CRP levels assessed in childhood, and is protective for
severe depression and/or psychosis assessed in early adulthood.
The analytic approach is informed by Mendelian randomization,
which posits that if a biomarker is causally related to a disease,
genetic variant(s) controlling activity of that biomarker should also
be associated with the disease (Burgess et al., 2015; Davey Smith
and Ebrahim, 2003). Using genetic variants as proxy for exposure
overcomes confounding because genetic variants are inherited at
random during meiosis, so are unrelated to potential confounders
(measured or unmeasured). Previous research has provided obser-
vational evidence for an association between IL-6, depression and
psychosis using population-based longitudinal (Gimeno et al.,
2009; Khandaker et al., 2014) and cross-sectional studies
(Dowlati et al., 2010; Goldsmith et al., 2016; Haapakoski et al.,
2015; Howren et al., 2009; Miller et al., 2011; Potvin et al., 2008;
Upthegrove et al., 2014). We show that Asp358Ala is strongly asso-
ciated with serum concentrations of IL-6 and CRP, but not with any
of the risk factors commonly linked with inflammation, depression
or psychosis. These findings indicate confounding is not a complete
explanation for previously observed associations between IL-6,
depression and psychosis.
The selection of a specific well-characterized genetic variant is
useful because it can serve as a proxy for drug actions. Epidemio-
logical genetic findings can be checked against a drug, so can
directly inform development of new treatments. Previous studies
of cardiovascular disease have used a similar genetic variant speci-
fic approach comparing effects of Asp358Ala with tocilizumab
(Collaboration et al., 2012; Swerdlow et al., 2012), and SNPs in
IL-1R locus with anakinra (IL-1R antagonist) (Interleukin 15 A > C).
value1 Depression Score, Median (IQR) Test Statistic; P-value2




































Fig. 2. Change in Serum IL-6 and CRP Concentrations at Age 9 Years per Copy of the Minor 358Ala Allele.
Table 3
Concentrations of Serum IL-6 and CRP at Age 9 years by the IL6R genotype Asp358Ala (rs2228145 A > C).
Inflammatory Marker IL6R
Genotype
Sample Mean (SD) F-statistic; P-value1
IL-6 (pg/ml)
A/A 1437 1.13 (1.42) F = 11.53; P = 1.1  105
A/C 2032 1.32 (1.69)2
C/C 748 1.46 (1.62)2
Total 4217 1.28 (1.60)
CRP (mg/L)
A/A 1442 0.83 (2.95) F = 1.83; P = 0.15
A/C 2037 0.84 (2.70)
C/C 748 0.62 (2.55)3
Total 4227 0.80 (2.76)
1 One-way Analysis of Variance was used to compare mean concentrations of IL-6 and CRP among groups with the AA, AC and CC genotype.
2 Calculation of increase in serum IL-6 mean concentration for one copy of C allele: compared with the AA group, mean IL-6 in the AC group was 0.19 pg/ml higher (i.e.,
16.8% increase from 1.13 pg/ml for one copy of the C allele). Compared with the AA group, mean IL-6 in the CC group was 0.33 pg/ml higher (i.e., 29.2% increase from 1.13 pg/
ml for two copy of the C allele). Therefore, average increase in mean IL-6 concentration for one copy of C allele is (16.8 + 29.2)  3 = 15.33%.
3 Calculation of decrease in mean CRP concentration in the group with CC, compared with AA, genotype: 0.83–0.62 = 0.21; (0.21  0.83)  100 = 25.3%.
Table 4
Association between IL6R Genotype Asp358Ala (rs2228145 A > C), Serum IL-6 and CRP Concentrations, and Other Risk Factors.
Risk Factor1 Age of Assessment Available Sample Statistic for Association2 P-value for Association
Inflammatory Markers
Serum IL-6 Level Mean 9.9y (SD = 0.32) 4217 0.182 (0.019) 5.5  1022
Serum CRP Level Mean 9.9y (SD = 0.32) 4227 0.110 (0.027) 3.5  105
Other Risk Factors
Age at Diagnosis of Depression and Psychosis Mean 17.8y (SD = 0.38) 3535 1.557 0.211
Sex At birth 8228 1.1132 0.573
Ethnicity At birth 7372 1.1462 0.564
Father’s Social Class At birth 6746 9.5682 0.654
Mother’s Highest Education At birth 7398 6.1442 0.631
Birth Weight At birth 7767 0.892 0.410
Gestational Age At birth 7864 0.679 0.507
Mother’s Postnatal Depression 8-week post-partum 7156 0.057 0.944
Childhood Behavioural Problems Mean 6.8y (SD = 0.11) 5718 0.555 0.574
Childhood Intelligence Mean 8.7y (SD = 0.32) 5509 0.353 0.702
Body Mass Index Mean 9.9y (SD = 0.32) 5813 1.52 0.218
1 Linear regression was used for IL-6 and CRP (natural logarithm transformed values); One Way Analysis of Variance was used for Age, birth weight, gestational age, Body
Mass Index, mother’s Edinburgh Postnatal Depression Score at 8 weeks postpartum, Strengths and Difficulties Questionnaire total difficulties score at 7 years, child’s total
Wechsler IQ score at 8 years.
2 Chi-squared test was used for sex, ethnicity, father’s social class, mother’s highest education.
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monoclonal antibody against the IL6R which inhibits both IL-6
classic and trans signaling (Calabrese and Rose-John, 2014).
Improvement in depressive symptoms after treatment with tocili-zumab in clinical trials (Gossec et al., 2015; Kappelmann et al.,
2016; Traki et al., 2014) is consistent with the observed protective
effect of Asp358Ala for severe depression in our epidemiological
sample.
270 G.M. Khandaker et al. / Brain, Behavior, and Immunity 69 (2018) 264–272The variant was not associated with total depression score,
which indicates that the IL6R pathway may be relevant for severe
rather than mild depression. An alternative explanation might be
age of assessment for depression and psychosis. Our sample was
relatively young (average age at assessment of outcomes 18 years).
A recent GAWS has reported that earlier-onset major depressive
disorder is genetically more similar to schizophrenia and bipolar
disorder than adult-onset major depression (Power et al., 2017).
Although results for severe depression and psychosis were similar,
indicating a protective effect of CC genotype, the ORs were not sta-
tistically significant. We observed a significant association with
Asp358Ala when severe depression and/or psychosis was used as
outcome. We combined severe depression and psychosis to
increase statistical power, and due to considerable overlap
between depression and psychosis in clinical presentation (APA,
2013), environmental and genetic risk factors (Green et al., 2010;
Smith et al., 2016).
To our knowledge, this is one of the first studies to examine the
association of Asp358Ala with depression, circulating inflamma-
tory markers and other psychiatric risk factors using the same
sample. Published literature on association between Asp358Ala
and schizophrenia is mixed. It has been reported that the CC, com-
pared with AA genotype, may decrease (Kapelski et al., 2015) or
increase (Hudson and Miller, 2016) risk of schizophrenia, while
one study did not find an association (Sun et al., 2008). A search
of existing GWAS results from the Psychiatric Genomics Consor-
tium revealed that Asp358Ala is associated with risks of
schizophrenia (P = 0.019) (Schizophrenia Working Group of the
Psychiatric Genomics, 2014), attention deficit hyperactivity disor-
der (P = 0.008) (Neale et al., 2010), but not with major depressive
disorder (P = 0.954) (Major Depressive Disorder Working Group
of the Psychiatric et al., 2013). The relatively young age of the sam-
ple and choice of outcome (severe depression and/or psychosis),
might explain difference with findings from previous studies.
Limitations of the work include a relatively small number of
cases of severe depression and psychosis in the ALSPAC cohort.
However, the cases were phenotypically well defined and were
of similar age, which might have aided detection of an association
with the genetic variant. Relatively young age of the sample pre-
cludes generalizability of findings to older adults. In future, studies
with larger samples and longer follow-up are required. Due to the
small number of cases, we have not examined associations
between Asp358Ala, depression and psychosis in male and female
participants separately. However, the association between
Asp358Ala and severe depression and/or psychosis remained sig-
nificant after controlling for sex. We have not carried out cell-
based functional experiments to examine the effects of Asp358Ala
on IL6R signaling in our participants. However, association of the
genetic variant (minor 358Ala allele) with decreased serum CRP
levels are consistent with an anti-inflammatory effect of this geno-
type downstream of IL-6 as demonstrated by others previously
(Ferreira et al., 2013). We have not carried out a two-stage least
squared regression analysis to obtain a Mendelian randomization
causal estimate for serum IL-6. Although Asp358Ala is associated
with serum IL-6 and soluble IL6R levels, it is not clear whether
the effect of Asp358Ala on risks of severe depression and/or psy-
chosis is mediated by specifically serum IL-6, soluble IL6R or
membrane-bound IL6R.
A potential role for IL-6 in pathogenesis of depression, psychosis
and other major mental disorders is supported by experimental
and clinical studies (Dantzer, 2004; Dantzer et al., 2008;
Khandaker and Dantzer, 2016; Miller et al., 2009; Raison et al.,
2006). Depression-like behaviour is observed in mice following
experimental immune-activation with injection of lipopolysaccha-
ride in peripheral circulation (O’Connor et al., 2009) or direct
intracerebroventricular injection of IL-6 (Sukoff Rizzo et al.,2012). IL-6 influences serotonin transporter levels and conse-
quently serotonin reuptake (Kong et al., 2015). Peripheral IL-6
plays a key role in mediating the effect of stress on brain as demon-
strated by experiments in mice (Hodes et al., 2014) and in human
volunteers (Harrison et al., 2009). In mice, inhibiting IL-6 with a
monoclonal antibody prevents depression-like behaviour follow-
ing exposures to stress (Hodes et al., 2014). Non-specific peripheral
immune activation caused by injection of lipopolysaccharide in
healthy volunteers increases serum IL-6 levels as well as inducing
low mood, anxiety and reduced cognitive performance
(Reichenberg et al., 2001). Inflammation-induced mood deteriora-
tion and associated changes in the subgenual cingulate activity and
mesolimbic connectivity are mediated by circulating IL-6 (Harrison
et al., 2009).
Low-grade inflammation might be a common mechanism
underlying the high comorbidity between depression, schizophre-
nia, CHD and diabetes. Longitudinal studies have shown that
higher serum concentrations of IL-6 increase future risks of heart
disease (Danesh et al., 2008), diabetes mellitus (Pradhan et al.,
2001), depression and psychosis (Khandaker et al., 2014). Previous
studies have reported that Asp358Ala has a protective effect on
heart disease (Collaboration et al., 2012; Swerdlow et al., 2012)
and type-1 diabetes (Ferreira et al., 2013), which is consistent with
our findings, and indicates a potentially causal role for inflamma-
tion in these illnesses.
Demonstrating a causal role for low-grade inflammation in
depression and psychosis may lead to new treatments. Elevated
serum inflammatory marker concentrations predict poor response
to antidepressants (Yoshimura et al., 2009) and antipsychotics
(Mondelli et al., 2015), while treatment resistant patients continue
to show elevated cytokine levels (Goldsmith et al., 2016; Maes
et al., 1997; O’Brien et al., 2007). Therefore, stratification of
patients according to their immune phenotype might aid predic-
tion of treatment response. Anti-inflammatory drugs such as
non-steroidal anti-inflammatory agents (Kohler et al., 2014) and
cytokine modulators (Kappelmann et al., 2016) may be helpful
for some patients with depression and schizophrenia (Muller
et al., 2002; Sommer et al., 2014). Recently, a proof-of-concept ran-
domised controlled trial (RCT) of infliximab, an anti-TNF mono-
clonal antibody, has reported improvements in patients with
treatment resistant depression characterized by high inflammation
at baseline (Raison et al., 2013). Based on human population-based
data our findings provide further evidence that the IL-6/IL6R path-
ways are involved in pathogenesis of severe depression and psy-
chosis. The field now needs RCTs of cytokine modulators
targeting IL-6/IL6R for patients with depression and psychosis,
specifically those with evidence of inflammation, to translate these
results into benefits for patients.
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